SWK (SWKH)
Market Price (3/30/2026): $17.14 | Market Cap: $207.3 MilSector: Financials | Industry: Asset Management & Custody Banks
SWK (SWKH)
Market Price (3/30/2026): $17.14Market Cap: $207.3 MilSector: FinancialsIndustry: Asset Management & Custody Banks
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 63% | Weak multi-year price returns3Y Excs Rtn is -40% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.8%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8%, Rev Chg QQuarterly Revenue Change % is -30% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 66%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 65% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.2% | |
| Attractive yieldFCF Yield is 13% | Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.96 | |
| Low stock price volatilityVol 12M is 44% | Key risksSWK key risks include [1] declining sales volumes in its key Tools & Outdoor segment, Show more. | |
| Megatrend and thematic driversMegatrends include Automation & Robotics, Sustainable Resource Management, and Sustainable & Green Buildings. Themes include Factory Automation, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 63% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 66%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 65% |
| Attractive yieldFCF Yield is 13% |
| Low stock price volatilityVol 12M is 44% |
| Megatrend and thematic driversMegatrends include Automation & Robotics, Sustainable Resource Management, and Sustainable & Green Buildings. Themes include Factory Automation, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -40% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.8%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8%, Rev Chg QQuarterly Revenue Change % is -30% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.2% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.96 |
| Key risksSWK key risks include [1] declining sales volumes in its key Tools & Outdoor segment, Show more. |
Qualitative Assessment
AI Analysis | Feedback
SWK (SWKH) stock has remained largely at the same level since 11/30/2025 because of the following key factors:
1. Stanley Black & Decker reported a miss on Q4 2025 net sales, which were down 1% year-over-year to $3.7 billion, and down 3% on an organic basis, falling short of analyst estimates of approximately $3.81 billion. This revenue decline was primarily attributed to softness in North American retail markets, indicating weaker underlying demand for its core Tools & Outdoor segment, which saw a 2.1% decrease in revenue to $3.16 billion. Despite adjusted earnings per share beating expectations, the revenue miss likely contributed to negative investor sentiment following the earnings release on February 4, 2026.
2. A cautious analyst rating and price target revision by Morgan Stanley on February 24, 2026, coincided with the start of the stock's decline. Morgan Stanley maintained an "Equal Weight" rating for SWK and set a price target of $87.00. This target was below Stanley Black & Decker's closing price of $89.25 on February 24, 2026, potentially signaling a lack of significant near-term upside or a more conservative outlook from an influential analyst, which may have prompted selling pressure.
Show more
1. Stanley Black & Decker reported a miss on Q4 2025 net sales, which were down 1% year-over-year to $3.7 billion, and down 3% on an organic basis, falling short of analyst estimates of approximately $3.81 billion. This revenue decline was primarily attributed to softness in North American retail markets, indicating weaker underlying demand for its core Tools & Outdoor segment, which saw a 2.1% decrease in revenue to $3.16 billion. Despite adjusted earnings per share beating expectations, the revenue miss likely contributed to negative investor sentiment following the earnings release on February 4, 2026.
2. A cautious analyst rating and price target revision by Morgan Stanley on February 24, 2026, coincided with the start of the stock's decline. Morgan Stanley maintained an "Equal Weight" rating for SWK and set a price target of $87.00. This target was below Stanley Black & Decker's closing price of $89.25 on February 24, 2026, potentially signaling a lack of significant near-term upside or a more conservative outlook from an influential analyst, which may have prompted selling pressure.
Show more
Stock Movement Drivers
Fundamental Drivers
The 0.7% change in SWKH stock from 11/30/2025 to 3/29/2026 was primarily driven by a 9.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.98 | 17.10 | 0.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 45 | 41 | -8.1% |
| P/S Multiple | 4.6 | 5.0 | 9.4% |
| Shares Outstanding (Mil) | 12 | 12 | 0.2% |
| Cumulative Contribution | 0.7% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SWKH | 0.7% | |
| Market (SPY) | -5.3% | 13.1% |
| Sector (XLF) | -10.0% | 25.8% |
Fundamental Drivers
The 14.7% change in SWKH stock from 8/31/2025 to 3/29/2026 was primarily driven by a 22.4% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.91 | 17.10 | 14.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 45 | 41 | -7.2% |
| P/S Multiple | 4.1 | 5.0 | 22.4% |
| Shares Outstanding (Mil) | 12 | 12 | 0.9% |
| Cumulative Contribution | 14.7% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SWKH | 14.7% | |
| Market (SPY) | 0.6% | -14.5% |
| Sector (XLF) | -10.8% | 1.9% |
Fundamental Drivers
The 27.0% change in SWKH stock from 2/28/2025 to 3/29/2026 was primarily driven by a 27.9% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.46 | 17.10 | 27.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43 | 41 | -2.5% |
| P/S Multiple | 3.9 | 5.0 | 27.9% |
| Shares Outstanding (Mil) | 12 | 12 | 1.8% |
| Cumulative Contribution | 27.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SWKH | 27.0% | |
| Market (SPY) | 9.8% | 3.4% |
| Sector (XLF) | -7.1% | 9.7% |
Fundamental Drivers
The 15.2% change in SWKH stock from 2/28/2023 to 3/29/2026 was primarily driven by a 22.1% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.85 | 17.10 | 15.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 47 | 41 | -11.1% |
| P/S Multiple | 4.1 | 5.0 | 22.1% |
| Shares Outstanding (Mil) | 13 | 12 | 6.1% |
| Cumulative Contribution | 15.2% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SWKH | 15.2% | |
| Market (SPY) | 69.4% | 9.8% |
| Sector (XLF) | 40.5% | 16.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SWKH Return | 36% | -10% | -1% | -10% | 37% | -1% | 49% |
| Peers Return | 18% | -13% | 10% | 1% | 11% | -18% | 3% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| SWKH Win Rate | 83% | 33% | 33% | 17% | 83% | 67% | |
| Peers Win Rate | 50% | 35% | 56% | 48% | 46% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| SWKH Max Drawdown | -9% | -17% | -12% | -14% | -1% | -5% | |
| Peers Max Drawdown | -13% | -31% | -11% | -12% | -16% | -20% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTS, SLRC, DHIL, GEG, ZSTK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | SWKH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -22.5% | -25.4% |
| % Gain to Breakeven | 29.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -48.5% | -33.9% |
| % Gain to Breakeven | 94.1% | 51.3% |
| Time to Breakeven | 154 days | 148 days |
| 2018 Correction | ||
| % Loss | -13.0% | -19.8% |
| % Gain to Breakeven | 14.9% | 24.7% |
| Time to Breakeven | 35 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -86.7% | -56.8% |
| % Gain to Breakeven | 650.0% | 131.3% |
| Time to Breakeven | 3,407 days | 1,480 days |
Compare to VRTS, SLRC, DHIL, GEG, ZSTK
In The Past
SWK's stock fell -22.5% during the 2022 Inflation Shock from a high on 12/29/2021. A -22.5% loss requires a 29.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About SWK (SWKH)
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
AI Analysis | Feedback
Here are 1-2 brief analogies for SWK Holdings Corporation (SWKH):
- It's like Hercules Capital (HTGC), a specialty lender to biotech and pharmaceutical companies, but SWK also has its own drug development pipeline.
- Imagine a hybrid of Royalty Pharma (RPRX), which invests in and finances pharmaceutical intellectual property, and a focused biotech company like Vertex Pharmaceuticals (VRTX), developing its own treatments.
AI Analysis | Feedback
```html- Customized Financing Solutions: SWK provides tailored financing solutions to a variety of life science companies in the healthcare sector.
- Investment Advisory Services: The company offers non-discretionary investment advisory services to institutional clients for investments in life science finance.
- Pharmaceutical Development & Licensing (Peptelligence Platform): SWK engages in pharmaceutical development, formulation, manufacturing, and licensing business utilizing its proprietary Peptelligence platform.
- Ovarest: An oral leuprolide tablet in SWK's product pipeline designed to treat endocrine disease.
AI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
Jody Staggs, President & CEO
Mr. Staggs joined SWK Holdings as a Senior Analyst in August 2015, was promoted to Managing Director in January 2020, and served as President and Interim CEO from September 2022 before being named CEO in January 2023. Prior to joining SWK, he was Vice President of Investments at Annandale Capital and was the first employee at Alistair Capital, a Dallas-based hedge fund. He also co-founded PBS Capital, an investment management business focused on pharmaceutical royalties and healthcare equities, which was a predecessor to SWK’s specialty finance business. Mr. Staggs previously worked as a Senior Portfolio Analyst at Highland Capital and a Senior Equity Research Associate at Raymond James.
Adam C. Rice, Chief Financial Officer
Mr. Rice was appointed as SWK Holdings’ Chief Financial Officer in July 2024, bringing over 18 years of finance and accounting leadership experience. He previously held the position of CFO at Park Cities Asset Management, an SEC registered alternative investment advisory firm. His career also includes various finance leadership roles within both public and private companies, particularly in the real estate sector. Mr. Rice began his career as a staff accountant at Ernst & Young.
Courtney Baker, Controller
Ms. Baker joined SWK Holdings as Assistant Controller in July 2023 and was promoted to Controller in June 2024. Her professional background includes expertise in technical accounting, SEC reporting, M&A activity, due diligence, purchase price allocation, and system integration. Before joining SWK, she worked for government services contractors in the defense and aerospace industry, and prior to that, in the financial services industry, specializing in system upgrades and process improvements.
Peter Blumberg, Vice President of Originations
Mr. Blumberg joined SWK Holdings as Vice President of Originations in March 2023. Before his time at SWK, he was an Associate at H.I.G. Capital, a leading middle-market private equity firm, where he was responsible for originating investment opportunities. He also worked at his family company, Blumberg Partners, and its subsidiary Blumberg Grain, focusing on business development and project management in North Africa. Mr. Blumberg started his career at J.P. Morgan Asset Management.
AI Analysis | Feedback
SWK Holdings Corporation (SWKH), a specialty finance company in the healthcare sector, faces several key risks to its business operations.- Potential for losses on principal invested in credit and royalty transactions: A primary risk stems from the nature of SWK's Finance Receivables segment, where the company may suffer losses on its principal invested in credit and royalty transactions. These investments often involve royalty streams or debt backed by royalty streams from small- to middle-market businesses, which are considered highly speculative and carry a high degree of credit loss risk. Additionally, investments in pharmaceutical and biologic products that are early in their commercial launch, face intense competition, or are subject to other risks, also present a high risk of principal loss if these underlying products fail to generate anticipated revenues.
- Highly competitive market for investment opportunities: SWK operates in a very competitive environment for investment opportunities within the life sciences sector. The company competes with a broad range of entities, including non-bank financial institutions, federal or state-chartered banks, venture debt funds, private equity funds, and pharmaceutical royalty funds. Many of these competitors possess greater financial resources and may have access to funding sources at a lower cost of capital, which could place SWK at a competitive disadvantage when vying for investment deals.
- Risks associated with the proposed merger with Runway Growth Finance Corp.: SWK Holdings Corporation is undergoing a proposed merger with Runway Growth Finance Corp. While this is positioned as a strategic move, it introduces immediate uncertainties. There have been discussions regarding potential dilution for shareholders from the deal, and management has cited a "modest delay" in closing the transaction, which could contribute to softer earnings in the short term. Furthermore, the adequacy of the price and process of this proposed sale is under investigation, indicating potential shareholder concerns.
AI Analysis | Feedback
nullAI Analysis | Feedback
SWK Holdings Corporation (SWKH) operates in two main segments: Finance Receivables and Pharmaceutical Development. The addressable markets for their key products and services are substantial both globally and within the U.S.Finance Receivables Segment
SWK provides customized financing solutions to a range of life science companies. The **global healthcare finance solutions market** was valued at approximately USD 153.45 billion in 2024 and is projected to reach USD 318.43 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 8.45% from 2025 to 2033. North America held a significant share, with the U.S. healthcare finance solutions market size valued at USD 51.94 billion in 2024 and expected to reach USD 95.54 billion by 2032, growing at a CAGR of 7.96% from 2025 to 2032. Other sources indicate the global market was USD 115.9 billion in 2022, projected to reach USD 276 billion by 2032 at a CAGR of 9.3%.Pharmaceutical Development Segment
Ovarest (oral leuprolide tablet)
Ovarest is an oral leuprolide tablet designed to treat endocrine disease. The broader **global leuprolide acetate market**, which includes various formulations (though injectables currently dominate), was valued at USD 2.91 billion in 2025 and is predicted to grow to approximately USD 4.62 billion by 2035, with a CAGR of 4.72% from 2026 to 2035. The U.S. leuprolide acetate market alone was estimated at USD 1.05 billion in 2025 and is expected to reach nearly USD 1.69 billion in 2035. North America held the largest share of the global leuprolide acetate market in 2025, accounting for 48%.Peptelligence Platform
SWK's Peptelligence platform is involved in pharmaceutical development, formulation, manufacturing, and licensing, particularly for peptide therapies. The **Peptelligence platform** itself has a projected U.S. market of USD 81.5 billion by 2034. More broadly, this platform falls within the **oral proteins and peptides market**, which globally was estimated to be worth USD 1.5 billion in 2023 and is anticipated to reach USD 8.4 billion by 2032, growing at a CAGR of 20% during that period. The **global peptide therapeutics market** was valued at USD 51.61 billion in 2025 and is projected to exceed USD 138.81 billion by 2035, expanding at a CAGR of over 10.4% from 2026 to 2035. North America is expected to command a 47.2% revenue share of the peptide therapeutics market by 2035. The **global drug delivery devices market** also provides a relevant context, as Peptelligence focuses on drug formulation and delivery. This market is projected to grow from USD 237.94 billion in 2026 to USD 335.71 billion by 2031, with oral delivery holding a 36.83% revenue share in 2025. The U.S. drug delivery systems market is specifically projected to reach USD 25.22 billion by 2032.AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for SWK Holdings Corporation (SWKH) over the next 2-3 years:
- Expansion of the Finance Receivables Portfolio: SWK Holdings is focused on growing its core specialty finance segment by consistently closing new financing transactions and providing add-on fundings to existing borrowers in the life science sector. This strategy has already led to a year-over-year increase in gross finance receivables. The company's management has expressed confidence in deploying capital into yielding finance receivables.
- Optimization of Yields on Finance Receivables: The company has demonstrated an ability to increase the effective and realized yields on its finance receivables portfolio. Higher yields on its financing solutions directly contribute to increased revenue from its existing and new investments.
- Strategic Management of the Pharmaceutical Development Segment: While the primary focus is on specialty finance, SWK Holdings is actively managing its Pharmaceutical Development segment (Enteris/MOD3 Pharma) to reduce operating expenses and generate revenue through strategic partnerships and asset sales. This includes exclusive option and purchase agreements with strategic partners that can lead to asset acquisitions and guaranteed revenue payments.
- Merger with Runway Growth Finance Corp.: A significant future revenue driver is the planned merger with Runway Growth Finance Corp. This transaction, announced in October 2025 and expected to close in late Q4 2025 or Q1 2026, will combine the operations and revenue streams of both entities, aiming to enhance the overall financial performance and scale of the combined company.
AI Analysis | Feedback
Share Repurchases
- In May 2025, SWK Holdings Corporation announced a new share repurchase program, authorizing the repurchase of up to $10 million of its common stock over the next year, concluding on May 19, 2026.
- From May 19, 2025, to June 30, 2025, the company repurchased 58,954 shares for approximately $0.87 million under the aforementioned program.
- Year-to-date as of August 2025, SWK had returned an additional $3 million of capital to shareholders through the repurchase of approximately 200,000 shares of its common stock.
Share Issuance
- SWK Holdings Corporation has not directly issued shares to raise capital in the last 3-5 years based on available information. However, as part of its acquisition by Runway Growth Finance Corp. in October 2025, $75.5 million in Runway Growth shares were to be issued to SWK's shareholders.
Inbound Investments
- In October 2025, Runway Growth Finance Corp. announced its definitive merger agreement to acquire SWK Holdings Corporation for an estimated purchase price of approximately $220 million. This acquisition consideration included a fixed stock component of $75.5 million in Runway Growth shares and approximately $145 million in cash.
Outbound Investments
- SWK Holdings, as a specialty finance company, regularly provides financing solutions to life science companies. As of March 31, 2025, its total investment assets were $227.8 million.
- In the first quarter of 2025, SWK committed a $15.0 million financing to ImpediMed Limited.
- The company's portfolio includes various structured credit and royalty financings, such as a $25.0 million structured credit to Elutia (August 2022) and a $20.0 million structured credit to Journey Medical Corporation (December 2023).
Capital Expenditures
- Information regarding specific dollar values of capital expenditures for SWK Holdings Corporation over the last 3-5 years is not available in the provided search results.
Trade Ideas
Select ideas related to SWKH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | NDAQ | Nasdaq | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | JEF | Jefferies Financial | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | ALAB | Astera Labs | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | PAYO | Payoneer Global | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | FOUR | Shift4 Payments | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.51 |
| Mkt Cap | 0.5 |
| Rev LTM | 74 |
| Op Inc LTM | 26 |
| FCF LTM | -9 |
| FCF 3Y Avg | 17 |
| CFO LTM | -8 |
| CFO 3Y Avg | 18 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -4.3% |
| Rev Chg 3Y Avg | 13.8% |
| Rev Chg Q | -12.7% |
| QoQ Delta Rev Chg LTM | -2.6% |
| Op Mgn LTM | 19.7% |
| Op Mgn 3Y Avg | 19.0% |
| QoQ Delta Op Mgn LTM | -3.8% |
| CFO/Rev LTM | -6.2% |
| CFO/Rev 3Y Avg | 8.7% |
| FCF/Rev LTM | -7.4% |
| FCF/Rev 3Y Avg | 7.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 3.2 |
| P/EBIT | 5.4 |
| P/E | 6.3 |
| P/CFO | -10.5 |
| Total Yield | 16.3% |
| Dividend Yield | 5.8% |
| FCF Yield 3Y Avg | 3.0% |
| D/E | 1.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.7% |
| 3M Rtn | -14.3% |
| 6M Rtn | -17.1% |
| 12M Rtn | -5.2% |
| 3Y Rtn | 2.6% |
| 1M Excs Rtn | 0.9% |
| 3M Excs Rtn | -5.6% |
| 6M Excs Rtn | -13.8% |
| 12M Excs Rtn | -16.6% |
| 3Y Excs Rtn | -57.3% |
Price Behavior
Price Behavior
| Market Price | $17.10 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -11.0% | |
| 50 Days | 200 Days | |
| DMA Price | $17.02 | $16.00 |
| DMA Trend | up | down |
| Distance from DMA | 0.5% | 6.9% |
| 3M | 1YR | |
| Volatility | 15.6% | 44.3% |
| Downside Capture | 0.16 | 0.13 |
| Upside Capture | 34.32 | 37.09 |
| Correlation (SPY) | 13.7% | 3.5% |
SWKH Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.18 | 0.16 | 0.22 | -0.49 | 0.07 | 0.21 |
| Up Beta | -0.22 | -0.05 | 0.20 | 0.23 | 0.13 | 0.22 |
| Down Beta | 0.12 | -0.02 | -0.06 | -2.15 | -0.19 | 0.01 |
| Up Capture | -6% | 8% | 22% | 20% | 17% | 8% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 17 | 24 | 49 | 107 | 355 |
| Down Capture | 72% | 54% | 48% | -4% | 12% | 54% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 23 | 34 | 69 | 133 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SWKH | |
|---|---|---|---|---|
| SWKH | 24.5% | 44.2% | 0.62 | - |
| Sector ETF (XLF) | -4.0% | 19.2% | -0.33 | 10.1% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 3.5% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 2.3% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -0.9% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 15.5% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SWKH | |
|---|---|---|---|---|
| SWKH | 8.3% | 29.6% | 0.30 | - |
| Sector ETF (XLF) | 9.1% | 18.7% | 0.37 | 16.1% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 14.2% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 5.0% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 1.1% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 18.6% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 10.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SWKH | |
|---|---|---|---|---|
| SWKH | 7.6% | 41.7% | 0.42 | - |
| Sector ETF (XLF) | 12.0% | 22.1% | 0.50 | 17.1% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 15.5% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 6.3% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 5.9% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 20.7% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 8.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2025 | -3.5% | -4.8% | -0.5% |
| 3/20/2025 | 6.7% | 4.6% | 39.0% |
| 7/19/2024 | 0.9% | 4.0% | 1.7% |
| 3/21/2024 | -0.4% | -3.0% | -1.5% |
| 11/9/2023 | -2.3% | -2.2% | 5.1% |
| 8/10/2023 | 0.4% | -1.1% | -3.3% |
| 4/3/2023 | -2.5% | -1.5% | -3.4% |
| 11/9/2022 | 1.7% | -0.3% | 0.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 5 | 9 |
| # Negative | 10 | 11 | 7 |
| Median Positive | 1.4% | 6.2% | 5.0% |
| Median Negative | -2.4% | -2.2% | -3.4% |
| Max Positive | 6.7% | 11.2% | 39.0% |
| Max Negative | -26.9% | -12.3% | -12.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/20/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/20/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.